New research suggests that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass far faster than those who end traditional diet and exercise regimens.
Published data in a major medical journal points out that while obese individuals can lose about a fifth of their total mass while using the jabs, the mass comes back at an average rate of nearly a kilo each month after stopping.
"Individuals buying such drugs should be aware of the potential of fast weight regain when the therapy ends," stated lead investigator Dr. Susan Jebb.
This pace of regain implies a return to pre-treatment weight within about one and a half years.
Comparing Treatments
The study, which looked at dozens of studies involving over 9,000 of participants, compared the outcomes of GLP-1 agonists with older methods.
Researchers note that individuals who lose weight through lifestyle changes alone typically have a more gradual creep back—perhaps 0.1 kg a month—post-intervention.
Understanding the Fast Rebound
Experts suggest the way of the drugs explains the accelerated weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which controls hunger.
"Long-term administration of the hormone levels several times higher than the body's typical production might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," said Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this medication means appetite is unsuppressed, making binge eating a significant risk."
A Chronic Disease?
Medical guidelines advise the jabs for people with obesity-related health risks, alongside recommended diet and exercise modifications.
Professionals contend that, given the likelihood of weight regain, the treatment might need to be ongoing.
This perspective is reinforced by drug manufacturers, who state that the results "emphasize the long-term nature of excess weight," comparing it to managing diseases like high blood pressure.
Patient Accounts
Users who have stopped the jabs explain a intense return of cravings.
"It felt as if a trigger flipping and I was suddenly ravenous," said a patient.
The struggle is compounded if individuals have not adopted lasting lifestyle or habit changes during therapy.
Widespread Use
Figures suggest that millions of adults in the UK have used these injections in the last 12 months, with demand continuing to grow.
- Adoption is more common among women than men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion access the medications through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while GLP-1 drugs are potent agents for weight loss, they are not a magic solution and long-term success hinges on combined behavioural support.
